StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Performance
Shares of NASDAQ VBIV opened at $0.56 on Friday. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $3.47. The firm has a market capitalization of $16.03 million, a price-to-earnings ratio of -0.05 and a beta of 1.93. The stock has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.61.
VBI Vaccines Company Profile
See Also
- Five stocks we like better than VBI Vaccines
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- The 3 Hottest Insiders Buys This Month
- Energy and Oil Stocks Explained
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- Want to Profit on the Downtrend? Downtrends, Explained.
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.